undamentalytics Newsletter
Sign in

Longeveron Inc. (LGVN) stock

Add to watchlist

Add holding +

NASDAQ: LGVN Nasdaq Biotechnology Next results ~November 4, 2026

C Fundamentals grade

Longeveron Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: share count (31m) is 10x the market-data count (3m).

Price vs value

Under review: share count (31m) is 10x the market-data count (3m). We'll show the comparison once resolved.

Longeveron Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds20 adding, 7 cuttingOf 5 active managers that changed their stake, 3 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Longeveron files

Where Longeveron stands after its latest 10-Q

Longeveron has little or no product revenue yet; it used $21m of cash in the twelve months to June 2026. That puts it 98 of 122 for growth among the biotechnology companies we cover. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 2 financial-health checks.

Our model value for Longeveron is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 12, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Longeveron Inc.'s trailing-twelve-month revenue fell 42.7% year on year, with a free-cash-flow margin of -1729.9%. Where it stands out: days sales outstanding of 20 days ranks 11 of 100 biotechnology companies we cover. Where it lags: free-cash-flow margin of -1729.9% ranks 150 of 176 biotechnology companies we cover.

Current signal Gross margin compressing: TTM gross margin fell to 69.8%, down 9.0pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 16 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 42.7% over the last 12 months.
  • Loss-making. Operating margin is -1992.8%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 1051.8 points on a year ago.
  • Burning cash. Free cash flow was -1729.9% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 132.8% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.

Latest results: FY2026 Q2

Filed August 12, 2026
Earnings per share
-$1.90 against an average estimate of -$1.90: beat by 0.0%
Revenue
$0m, down 9.2% on a year earlier
Share reaction
+0.9% in the first session after the results on August 12, 2026, against +0.9% for the S&P 500
Next report
November 4, 2026

Longeveron's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+3.5%
  • 1 week+2.3%
  • 1 month-31.4%
  • This year-66.2%
  • 1 year-78.7%
  • 5 years-99.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.2M
Operating margin
-1992.8%
Net margin
-1977.6%

Growth

Revenue growth
−42.7%
Change in growth rate
+2.6 pts

Cash

Free cash flow (TTM)
-$20.5M
FCF margin
-1729.9%
Stock pay % of revenue
132.8%

Earnings

Last results
August 12, 2026
Next results (est.)
November 16, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Leadership
  3. Announcement
  4. Announcement
  5. Announcement
  6. Leadership
  7. Results
  8. Announcement
  9. Leadership
  10. Leadership
  11. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Longeveron Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: share count (31m) is 10x the market-data count (3m): held for review.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025
Share price$1207.00$322.00$136.00$17.30$5.06
Market value$22.8bn$6.8bn$295.6bn$162.8bn$88.9bn
+ Net debt (− = net cash)−$23m−$8m−$5m−$19m−$5m
Enterprise value$22.8bn$6.7bn$295.6bn$162.8bn$88.9bn
Multiples
Price / sales n/mn/mn/mn/mn/m
Price / earnings —————
Price / free cash flow —————
EV / EBITDA —————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

19 /100

Weak moat

How hard Longeveron's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -103.3% of total assets over 6 years.

  • Pricing power 9 / 20

    Gross margin has been a median 51.3%, moving by 19.8 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -1388.2%; its worst year was -2364.6%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 5 years, at a median -1349.4% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (24 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $509000 for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$7.63 +41% $2m +46%
Next −$4.93 +35% $9m +397%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +12.3% on 90 days ago. In the last 30 days, 1 analyst raised Longeveron Inc.'s forecast and 1 cut it.

Consensus EPS forecast Longeveron Inc., last 90 days
−$8.00 −$6.00 −$4.00 −$2.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$6.80 Current fiscal year, 60 days ago: −$6.80 Current fiscal year, 30 days ago: −$7.20 Current fiscal year, 7 days ago: −$7.20 Current fiscal year, Now: −$7.63 −$7.63 Next fiscal year, 90 days ago: −$4.60 Next fiscal year, 60 days ago: −$4.60 Next fiscal year, 30 days ago: −$4.70 Next fiscal year, 7 days ago: −$4.70 Next fiscal year, Now: −$4.93 −$4.93

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$6.80−$4.60
60 days ago −$6.80−$4.60
30 days ago −$7.20−$4.70
7 days ago −$7.20−$4.70
Now −$7.63−$4.93

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$1.90 −$1.90 0.0%
Mar 2026 −$1.73 −$1.90 −10.1%
Dec 2025 −$3.67 −$2.20 +40.0%
Sept 2025 −$2.57 −$3.90 −51.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 12, 2026

No numeric guidance in Longeveron Inc.'s latest earnings release (filed August 12, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

2 analysts, Oct 2026
Buy150%
Hold150%
Sell00%

Monthly trend

  1. Oct 2026112
  2. Sep 2026213

Counts of recommendations published by analysts covering Longeveron Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
2.5%
of tradable shares
Days to cover
0.42
at average volume
Short interest, 1 month
−66%
to October 15, 2026
Held by institutions
23%
of shares
Held by insiders
14.8%
of shares
Employees
38
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −79.5%

$8.34 on October 31, 2025 to $1.71

ThenNowEffect
Revenue (last 12 months) $2m $1m −42.7%
P/S multiple n/m n/m −62.8%
Share count 10403m 10801m −3.7%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
LGVN−73%−58%−87%−71%−66%
Industry peers (median)−56%−17%−28%−5%−26%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
LGVN25%33%25%42%27%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
LGVN−82%−71%−94%−75%−88%
S&P 500−25%−10%−8%−19%−9%

Worst fall since February 12, 2021: 100% from November 24, 2021 to October 16, 2026. Getting back needed a 304217% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.39 – $11.60
From 52-week high
−85.3%
vs 50-day average
−54.6%
vs 200-day average
−74.2%
Volatility (1 year)
123%
Beta vs S&P 500
0.58

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±7.2%
After a week
2 up, 10 down
typical move ±9.7%
After a month
5 up, 7 down
typical move ±13.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 12, 2026 +0.9% +0.9% +18.8% +5.9%
May 13, 2026 −6.3% +1.4% −5.7% +4.4%
November 4, 2025 −8.3% −0.8% −13.7% −23.8%
August 13, 2025 +10.9% +0.4% +17.5% +15.7%
May 8, 2025 −10.1% +0.6% −6.0% −14.8%
February 28, 2025 −9.8% −0.2% −1.3% +1.3%
November 12, 2024 −2.3% −0.3% −14.7% −14.3%
August 14, 2024 −7.5% +2.0% −3.8% −21.8%
May 12, 2023 −6.1% +0.2% −4.3% +9.6%
March 10, 2023 −15.5% −1.6% −19.5% −17.5%
November 14, 2022 +5.1% 0.0% 0.0% −14.1%
August 12, 2022 +3.9% +2.1% −11.1% −18.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Longeveron Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Longeveron Inc.
$0 $1M $2M $3M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $767K Revenue (TTM), FY23 Q4: $709K Revenue (TTM), FY24 Q1: $978K Revenue (TTM), FY24 Q2: $1.2M Revenue (TTM), FY24 Q3: $1.9M Revenue (TTM), FY24 Q4: $2.4M Revenue (TTM), FY25 Q1: $2.2M Revenue (TTM), FY25 Q2: $2.1M Revenue (TTM), FY25 Q3: $1.4M Revenue (TTM), FY25 Q4: $1.2M Revenue (TTM), FY26 Q1: $1.2M Revenue (TTM), FY26 Q2: $1.2M $1.2M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $767K
FY23 Q4 $709K
FY24 Q1 $978K
FY24 Q2 $1.2M
FY24 Q3 $1.9M
FY24 Q4 $2.4M
FY25 Q1 $2.2M
FY25 Q2 $2.1M
FY25 Q3 $1.4M
FY25 Q4 $1.2M
FY26 Q1 $1.2M
FY26 Q2 $1.2M
Revenue growth, TTM YoY Longeveron Inc.
-100% 0% 100% 200% 300% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -41.5% Revenue growth, TTM YoY, FY23 Q4: -42.0% Revenue growth, TTM YoY, FY24 Q1: -13.5% Revenue growth, TTM YoY, FY24 Q2: 39.3% Revenue growth, TTM YoY, FY24 Q3: 141.5% Revenue growth, TTM YoY, FY24 Q4: 237.4% Revenue growth, TTM YoY, FY25 Q1: 127.5% Revenue growth, TTM YoY, FY25 Q2: 68.7% Revenue growth, TTM YoY, FY25 Q3: -22.4% Revenue growth, TTM YoY, FY25 Q4: -49.9% Revenue growth, TTM YoY, FY26 Q1: -45.3% Revenue growth, TTM YoY, FY26 Q2: -42.7% -42.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -41.5%
FY23 Q4 -42.0%
FY24 Q1 -13.5%
FY24 Q2 39.3%
FY24 Q3 141.5%
FY24 Q4 237.4%
FY25 Q1 127.5%
FY25 Q2 68.7%
FY25 Q3 -22.4%
FY25 Q4 -49.9%
FY26 Q1 -45.3%
FY26 Q2 -42.7%
Operating margin (TTM) Longeveron Inc.
-3000% -2000% -1000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -2715.8% Operating margin (TTM), FY23 Q4: -2966.0% Operating margin (TTM), FY24 Q1: -2086.2% Operating margin (TTM), FY24 Q2: -1480.1% Operating margin (TTM), FY24 Q3: -954.6% Operating margin (TTM), FY24 Q4: -690.6% Operating margin (TTM), FY25 Q1: -791.5% Operating margin (TTM), FY25 Q2: -941.1% Operating margin (TTM), FY25 Q3: -1542.7% Operating margin (TTM), FY25 Q4: -1942.2% Operating margin (TTM), FY26 Q1: -1881.7% Operating margin (TTM), FY26 Q2: -1992.8% -1992.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -2715.8%
FY23 Q4 -2966.0%
FY24 Q1 -2086.2%
FY24 Q2 -1480.1%
FY24 Q3 -954.6%
FY24 Q4 -690.6%
FY25 Q1 -791.5%
FY25 Q2 -941.1%
FY25 Q3 -1542.7%
FY25 Q4 -1942.2%
FY26 Q1 -1881.7%
FY26 Q2 -1992.8%
FCF margin (TTM) Longeveron Inc.
-3000% -2000% -1000% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -2283.7% FCF margin (TTM), FY23 Q4: -2722.6% FCF margin (TTM), FY24 Q1: -1688.7% FCF margin (TTM), FY24 Q2: -1349.4% FCF margin (TTM), FY24 Q3: -826.0% FCF margin (TTM), FY24 Q4: -607.1% FCF margin (TTM), FY25 Q1: -725.6% FCF margin (TTM), FY25 Q2: -730.4% FCF margin (TTM), FY25 Q3: -1181.6% FCF margin (TTM), FY25 Q4: -1575.5% FCF margin (TTM), FY26 Q1: -1524.3% FCF margin (TTM), FY26 Q2: -1729.9% -1729.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -2283.7%
FY23 Q4 -2722.6%
FY24 Q1 -1688.7%
FY24 Q2 -1349.4%
FY24 Q3 -826.0%
FY24 Q4 -607.1%
FY25 Q1 -725.6%
FY25 Q2 -730.4%
FY25 Q3 -1181.6%
FY25 Q4 -1575.5%
FY26 Q1 -1524.3%
FY26 Q2 -1729.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 6 1 1 1 2 1 1
Gross profit 2 1 0 0 2 1 1
EBITDA −4 −17 −17 −20 −16 −22 −23
Operating income −4 −17 −18 −21 −17 −23 −24
Net income −4 −17 −19 −21 −16 −23 −23
Diluted EPS −$0.23 −$0.90 −$0.90 −$10.22 −$2.62 −$1.29 —
Growth (year on year)
Revenue — −76.8% −6.4% −42.0% +237.4% −49.9% −42.7%
Margins
Gross margin 32.4% 45.2% 40.7% 31.2% 78.8% 67.0% 69.8%
EBITDA margin −67.1% <−999% <−999% <−999% −661.5% <−999% <−999%
Operating margin −67.1% <−999% <−999% <−999% −690.7% <−999% <−999%
Net margin −66.1% <−999% <−999% <−999% −667.8% <−999% <−999%
Free-cash-flow margin −44.3% −763.1% <−999% <−999% −607.1% <−999% <−999%
Cash flow
Cash from operations −2 −10 −14 −19 −14 −19 −20
Capital spending 0 0 1 0 1 0 0
Free cash flow −2 −10 −15 −19 −15 −19 −21
Stock-based pay 0 1 2 2 2 2 2
Free cash flow after stock pay −3 −11 −17 −21 −17 −21 −22
Balance sheet
Cash 1 26 11 5 19 5 10
Total debt 3 3 2 — 0 0 0
Net debt (negative = net cash) 3 −23 −8 −5 −19 −5 −10
Diluted shares 16m 19m 21m 2,173m 9,411m 17,577m —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $15m
Short-term assets $11mLonger-term assets $4m
What it owes, and who funded it · $15m
Short-term liabilities $4mLonger-term liabilities $1mShareholders' equity $10m
  • Short-term assets cover short-term liabilities $11m of assets due within a year against $4m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $11m short-term assets against $778,000 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Longeveron Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
1018.1%
of revenue
Days sales outstanding
20 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated LGVN DARE STTK RNAC MNOV ABSI Median
Revenue, last 12 months $1m $1m $1m $1m $920481 $2m $56m
Revenue growth, last 12 months −42.7% >999% −66.6% 44.0% 875.7% −62.3% 12.6%
Revenue growth, 3-year average 10.4% — 5.2% −68.8% — −43.3% 13.7%
Revenue growth, latest quarter −9.2% 499.6% −66.6% −100.0% 240.6% −46.4% 10.2%
Gross margin 69.8% — — — 100.0% — 82.9%
Operating margin <−999% −813.4% <−999% <−999% <−999% <−999% −189.4%
Operating margin, 3-year average <−999% >999% <−999% <−999% −905.8% <−999% −363.5%
Net margin <−999% −804.4% <−999% <−999% <−999% <−999% −169.8%
Cash from operations / revenue <−999% −826.8% <−999% <−999% −989.7% <−999% −168.0%
Free-cash-flow margin <−999% −860.6% <−999% <−999% −991.2% <−999% −162.4%
Free-cash-flow margin, 3-year average <−999% >999% <−999% <−999% <−999% <−999% −310.0%
Stock pay / revenue 132.8% 110.0% 853.2% 625.6% 100.3% >999% 20.0%
Change in share count — 62.5% 15.3% 143.3% 0.2% 26.0% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -42.7% 12.6% 139 of 172
Change in growth rate Growth +2.6pp -0.1pp 63 of 172
Gross margin Profitability 69.8% 82.4% 53 of 75
Operating margin Profitability -1992.8% -189.4% 145 of 175
Net margin Profitability -1977.6% -157.3% 151 of 180
Free-cash-flow margin Cash generation -1729.9% -145.4% 150 of 176
Stock pay as % of revenue Cash generation 132.8% 19.2% 143 of 179
Days sales outstanding Balance sheet 20 days 75 days 11 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Clinical Trial Revenue $954,000 79.6% ▼ 32.0%
Contract Manufacturing Revenue $222,000 18.5% ▼ 54.4%
Contract Manufacturing Lease Revenue $23,000 1.9% ▼ 95.4%

From Longeveron Inc.'s 10-K filed March 17, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$3.3M
Institutions reporting
39
Shares held vs prior quarter
▲ 109.0%
Positions opened / closed
13 / 4

Top buyers and sellers, Q2 2026: 20 institutions bought and 7 sold ; the biggest buyer was Logos Global Management LP (+1.3M shares) and the biggest seller HRT Financial LP (−119K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Millennium Management LLC $951,778 1.4M 28.4% ▲ 203.1%
Logos Global Management LP $904,761 1.3M 27.0% New
Vanguard Capital Management LLC $408,657 581K 12.2% ▲ 7.2%
Blackrock, Inc. $157,592 224K 4.7% 0.0%
Geode Capital Management, LLC $143,244 204K 4.3% ▲ 0.1%
Jane Street Group, LLC $133,831 190K 4.0% ▲ 2.5%
Vanguard Fiduciary Trust Co $98,509 140K 2.9% ▲ 261.9%
Mariner, LLC $88,578 126K 2.6% New
ADAR1 Capital Management, LLC $76,209 108K 2.3% ▼ 45.8%
Beacon Pointe Advisors, LLC $70,300 100K 2.1% 0.0%
Virtu Financial LLC $41,000 59K 1.2% New
Two Sigma Securities, LLC $39,349 56K 1.2% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Longeveron Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 16, 2026 estimated from the company's past filing pattern, not announced

  • August 12, 2026
  • May 13, 2026
  • November 4, 2025
  • August 13, 2025
  • May 8, 2025
  • February 28, 2025

Recent SEC filings

Data status

When each part of this page on Longeveron Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Longeveron Inc. in brief

What does Longeveron Inc. do?
Longeveron Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Longeveron Inc.'s stock ticker?
Longeveron Inc. trades under the ticker LGVN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Longeveron Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Longeveron Inc. reported revenue of $1.2M, 42.7% lower than a year earlier, according to its SEC filings.
What is Longeveron Inc.'s free cash flow?
Longeveron Inc.'s free-cash-flow margin is -1729.9% of revenue over the trailing twelve months, ranking 150 of the 176 biotechnology companies we cover.
Who are Longeveron Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Millennium Management LLC, Logos Global Management LP and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Longeveron Inc.'s market cap?
On December 31, 2025, Longeveron Inc.'s market capitalisation was about $88.9B and net debt of -$4.7M. Market figures come from third-party market data and may be delayed.
Who are Longeveron Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Longeveron Inc. are Dare Bioscience, Inc., Shattuck Labs, Inc., Cartesian Therapeutics, Inc., Medicinova Inc and Absci Corp. The side-by-side comparison below sets their revenue, margins and growth against Longeveron Inc.'s.
When is Longeveron Inc.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Longeveron Inc. announces its own schedule.